ABSTRACT
Glucagon-like peptide-1 receptor agonists (GLP-1RA) have been reported to increase the risk of acute pancreatitis (AP). This real-world study did not observe a higher frequency of AP with GLP-1RA exposure in adults with T2D and a prior history of AP regardless of etiology.
Subject(s)
Atherosclerosis/prevention & control , Dyslipidemias/therapy , Adolescent , Adult , Atherosclerosis/economics , Atherosclerosis/etiology , Child , Combined Modality Therapy/economics , Cost Savings , Diet, Fat-Restricted , Drug Monitoring , Dyslipidemias/economics , Dyslipidemias/metabolism , Dyslipidemias/physiopathology , Female , Health Care Costs , Humans , Hypolipidemic Agents/adverse effects , Hypolipidemic Agents/economics , Hypolipidemic Agents/therapeutic use , Insulin Resistance , Lipids/blood , Male , Motor Activity , Risk Factors , Smoking Cessation , United States/epidemiologySubject(s)
Atherosclerosis/prevention & control , Dyslipidemias/therapy , Adolescent , Adult , Atherosclerosis/economics , Atherosclerosis/etiology , Child , Combined Modality Therapy/economics , Cost Savings , Diet, Fat-Restricted , Drug Monitoring , Dyslipidemias/economics , Dyslipidemias/metabolism , Dyslipidemias/physiopathology , Female , Health Care Costs , Humans , Hypolipidemic Agents/adverse effects , Hypolipidemic Agents/economics , Hypolipidemic Agents/therapeutic use , Insulin Resistance , Lipids/blood , Male , Motor Activity , Risk Factors , Smoking Cessation , United States/epidemiologyABSTRACT
Inhaled insulin offers a novel option for controlling blood glucose levels in type 1 and type 2 diabetes, obviating the need for multiple daily injections. The first of several delivery systems, insulin Exubera, was recently approved by the US Food and Drug Administration (FDA). However, questions remain regarding its efficacy, cost-effectiveness, and possible deleterious effects on pulmonary function. This review will discuss the pharmacology, efficacy, important clinical trials, and practical aspects of inhaled insulin, and potential concerns associated with its use.
Subject(s)
Diabetes Mellitus/drug therapy , Hypoglycemic Agents/administration & dosage , Insulin/administration & dosage , Administration, Inhalation , Blood Glucose/metabolism , Diabetes Mellitus/blood , Humans , Hypoglycemic Agents/therapeutic use , Insulin/therapeutic use , Treatment OutcomeABSTRACT
OBJECTIVE: Glycemic control using inhaled, dry-powder insulin plus a single injection of long-acting insulin was compared with a conventional regimen in patients with type 2 diabetes, which was previously managed with at least two daily insulin injections. RESEARCH DESIGN AND METHODS: Patients were randomized to 6 months' treatment with either premeal inhaled insulin plus a bedtime dose of Ultralente (n = 149) or at least two daily injections of subcutaneous insulin (mixed regular/NPH insulin; n = 150). The primary efficacy end point was the change in HbA1c from baseline to the end of study. RESULTS: HbA1c decreased similarly in the inhaled (-0.7%) and subcutaneous (-0.6%) insulin groups (adjusted treatment group difference: -0.07%, 95% CI -0.32 to 0.17). HbA1c < 7.0% was achieved in more patients receiving inhaled (46.9%) than subcutaneous (31.7%) insulin (odds ratio 2.27, 95% CI 1.24-4.14). Overall hypoglycemia (events per subject-month) was slightly lower in the inhaled (1.4 events) than in the subcutaneous (1.6 events) insulin group (risk ratio 0.89, 95% CI 0.82-0.97), with no difference in severe events. Other adverse events, with the exception of increased cough in the inhaled insulin group, were similar. No difference in pulmonary function testing was seen. Further studies are underway to assess tolerability in the longer term. Insulin antibody binding increased more in the inhaled insulin group. Treatment satisfaction was greater in the inhaled insulin group. CONCLUSIONS: Inhaled insulin appears to be effective, well tolerated, and well accepted in patients with type 2 diabetes and provides glycemic control comparable to a conventional subcutaneous regimen.
Subject(s)
Diabetes Mellitus/drug therapy , Insulin, Long-Acting/administration & dosage , Insulin/administration & dosage , Administration, Inhalation , Adult , Aged , Aged, 80 and over , Biological Availability , Blood Glucose/analysis , Blood Glucose/drug effects , Confidence Intervals , Diabetes Mellitus/diagnosis , Dose-Response Relationship, Drug , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Injections, Subcutaneous , Male , Middle Aged , Odds Ratio , Reference Values , Risk Assessment , Severity of Illness Index , Treatment OutcomeABSTRACT
Because thyroid cancer cells express functional TSH receptors (TSHR), TSHR-mRNA in peripheral blood might serve as a tissue-/cancer-specific marker. We measured circulating TSHR-mRNA by RT-PCR in 51 normal controls, 27 patients with benign thyroid disease, 67 patients with treated differentiated thyroid cancer (DTC), and eight patients with newly diagnosed DTC, preoperatively. Results were compared with thyroglobulin (Tg) mRNA and serum Tg levels. TSHR-mRNA signals were not detected in normal controls and in 24 of 27 (89%) patients with benign thyroid disease. All 19 patients with treated DTC with evidence of distant or local disease tested positive for TSHR-mRNA (sensitivity 100%). Among patients with no evidence of disease, TSHR-mRNA was detected in 1 in 48 (specificity 98%). Six of the eight newly diagnosed DTC patients tested preoperatively were positive for TSHR-mRNA. The concordance between TSHR-mRNA and Tg-mRNA and between TSHR-mRNA and serum Tg was 95%. Fourteen patients with DTC (21%) had Tg antibodies, three with local disease (all positive for TSHR-mRNA), and 11 with no evidence of disease (all negative for TSHR-mRNA). Our results indicate that TSHR-mRNA and/or Tg-mRNA in peripheral blood are both equally sensitive and specific markers for monitoring thyroid cancer patients. Their principal value resides in the Tg antibody-positive patients in whom a positive or a negative mRNA value might have indicated or obviated the need for a whole-body scan. Furthermore, the high specificity combined with their ability to predict thyroid cancer preoperatively suggests a potential role in detecting thyroid cancer in patients with thyroid nodules.
Subject(s)
Receptors, Thyrotropin/blood , Thyroglobulin/blood , Thyroid Neoplasms/blood , Thyroid Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Autoantibodies/blood , Biomarkers, Tumor/blood , Case-Control Studies , Female , Humans , Male , Middle Aged , RNA, Messenger/blood , Receptors, Thyrotropin/genetics , Sensitivity and Specificity , Thyroglobulin/genetics , Thyroglobulin/immunologyABSTRACT
OBJECTIVE: To describe an unusual case of development of diabetes mellitus (DM) several years after manifestation of diabetic nephropathy and to review the related literature. METHODS: We present a case report, including detailed laboratory and pathologic findings in a 51-year-old man who was diagnosed as having DM several years after presenting with diabetic nephropathy. The pertinent literature is also reviewed. RESULTS: A 51-year-old African American man presented with proteinuria of 4 g/24 h. Past medical history was significant for impaired glucose tolerance diagnosed 2 years previously. Subsequent follow-up demonstrated fasting blood glucose levels ranging from 108 to 123 mg/dL and glycated hemoglobin levels ranging from 5.3 to 5.8%. The patient also had chronic hepatitis C, hypertension, a history of intravenous drug abuse, and a family history of DM and hypertension. On examination of the patient, his blood pressure was 180/90 mm Hg. Funduscopy revealed mild diabetic retinopathy. Work-up was negative for glomerulonephritis, connective tissue disease, vasculitis, or multiple myeloma. Kidney biopsy revealed thickened glomerular basement membranes and diffuse glomeru-losclerosis, consistent with diabetic nephropathy. During follow-up, 9 years after presenting with proteinuria and 4 years after diagnosis of biopsy-proven diabetic nephropathy, the patient had a blood glucose level of 890 mg/dL and diabetic ketoacidosis. CONCLUSION: This case provides one explanation for the natural course of patients who present with "diabetic complications" but have no diabetes. Some of those patients may have "prediabetes" and may manifest with DM during follow-up. We also conclude that hyperglycemia is not the only important factor in the pathogenesis of diabetic nephropathy.
Subject(s)
Diabetes Mellitus, Type 2/pathology , Diabetic Nephropathies/pathology , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/diagnosis , Diabetic Nephropathies/diagnosis , Diabetic Retinopathy/pathology , Glycated Hemoglobin/metabolism , Humans , Hypertension/complications , Hypertension/drug therapy , Kidney/pathology , Male , Middle AgedABSTRACT
Although polycystic ovary syndrome (PCOS) is associated with hyperandrogenism and infertility early in life, it is a harbinger of a lifelong condition that can lead to serious sequelae such as endometrial or ovarian cancer, diabetes mellitus, and coronary artery disease. We review the pathophysiology, diagnosis, and treatment of this condition.